Loading...

The current price of MYNZ is 1.035 USD — it has increased 0.49 % in the last trading day.
Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
Wall Street analysts forecast MYNZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MYNZ is 14.00 USD with a low forecast of 14.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Mainz Biomed NV revenue for the last quarter amounts to 214.76K USD, decreased % YoY.
Mainz Biomed NV. EPS for the last quarter amounts to -0.27 USD, decreased % YoY.
Mainz Biomed NV (MYNZ) has 19 emplpoyees as of December 15 2025.
Today MYNZ has the market capitalization of 8.84M USD.